Navigation Links
Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
Date:9/27/2010

NEW YORK, Sept. 27 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the JMP Securities Healthcare Conference, being held at the New York Palace Hotel in New York City.  Mr. Bentsur's presentation is scheduled to take place tomorrow, Tuesday, September 28, 2010, at 1:00 p.m.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex™ (ferric citrate), an oral, iron-based compo
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
3. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
4. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
5. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
10. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
11. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... YORK , 21. Mai 2015 ... DPRX ), ein Unternehmen für ... auf die Entwicklung und Vermarktung von ... konzentriert, kündigte heute eine wissenschaftliche Posterpräsentation ... Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 und ...
(Date:5/21/2015)... -- Heidrick & Struggles (Nasdaq: HSII ), the premier ... and culture shaping worldwide, strengthens its ... the addition of Tim Dietlin to the ... Dietlin has extensive life sciences and professional services ... and Commercial functions to increase productivity, drive transformational change, ...
(Date:5/21/2015)... , May 21, 2015  Today, ... physicians who prescribe biologics – Alliance for ... American College of Rheumatology, Biologics Prescribers Collaborative, ... Organizations, Endocrine Society, and North American Society ... sent a letter to U.S. Food and ...
Breaking Medicine Technology:Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7Heidrick Increases Healthcare and Life Sciences Expertise 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 3Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 4
... 23, 2007 /PRNewswire-FirstCall/ -- Shire plc,announced that ... non-oral medication approved for treatment of,Attention Deficit ... 12 years, provided significant improvement in symptom ... 12-month open-label,study presented at the American Psychiatric ...
... Underscores Impact of Disease on Work Status and,Productivity, ... at Digestive Disease Week(R) 2007 (DDW), from,long-term extensions ... 2) show that subjects with moderately to severely ... in the blinded phase of the trials maintained,improvement ...
Cached Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9
(Date:5/24/2015)... NC (PRWEB) May 24, 2015 Scientists ... a paper on air quality compliance issues that may ... American workers. Surviving Mesothelioma has just posted an article ... now. , The group found airborne asbestos levels ... data collected between 1984 and 2011. , “Asbestos compliance ...
(Date:5/24/2015)... Indianapolis, Indiana (PRWEB) May 24, 2015 ... network service provider announces Midwest Telecom of America, Inc. ... , According to Cory Childs, IFN Enterprise Sales ... to service providers. “IFN’s fiber transport provides MTA ... Operations Center to their Tier 1 Internet and voice ...
(Date:5/23/2015)... Florida City, FL (PRWEB) May 23, 2015 ... together to build a new playground for Branches Florida City ... destroyed the former play space in 2010. , A large ... then new playground on May 23, 2010 in the middle ... families watched. The fire was later declared arson even though ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 On Wednesday, ... that, “the company has been the target of a ... part of the company’s ongoing Information Technology (IT) security ... insurers.” , The most notable attack on health ... Anthem Inc., the nation’s second largest health insurer, revealed ...
(Date:5/23/2015)... Javon Bea Mercy Health System ... and Rehabilitation Center, 557 N. Washington St., Janesville, will ... 20, 5:30-6:30 pm. , The 8-week clinic is lead ... RN, BSN, who will offer training that encompasses a ... mechanics and show selection and weekly training plans. , ...
Breaking Medicine News(10 mins):Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4
... Disability,Management Specialists Commission (CDMSC) has chosen the University ... its 2007 Quality,Leadership Award, in recognition of the ... of its workforce. The award was presented ... Joint Forum on Health, Productivity, and Absence Management,in ...
... In a pioneering effort, Children,s,Hospital of Pittsburgh ... of,Medicine have joined forces to launch a new ... pediatric research. The potential of this initiative ... through a groundbreaking gift of $23 million. The,gift ...
... MSA (NYSE: MSA ), the,global leader in ... people,s health and safety, announced today that it,will broadcast ... the,Internet on Thursday, November 1, 2007 at 10:00 a.m. ... and interested parties will have the opportunity to listen ...
... Caraco Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) posted record ... of fiscal 2008, ended September 30, 2007, of,$41.4 million ... $53.0 million for the corresponding periods of fiscal 2007. ... quarter and first six,months of fiscal 2007, respectively. Net ...
... Could some of the natural chemicals found ... health" Researchers at Wake Forest University Baptist Medical ... evaluate the potential cardiovascular health effects of Natures ... are evaluating the influence of this supplement on ...
... TORONTO, Oct. 24 /PRNewswire-FirstCall/ - Predictive medicine ... that clinical data and,preliminary actuarial analysis on its ... and valuable cardiovascular risk assessment tool for the,life ... the PREVU(x),line of skin cholesterol tests and has ...
Cached Medicine News:Health News:UPMC and UPMC Health Plan Recognized Nationally for Quality Leadership in Employee Health and Productivity 2Health News:UPMC and UPMC Health Plan Recognized Nationally for Quality Leadership in Employee Health and Productivity 3Health News:Collaboration to Create Pediatric Research Institute Receives $23 Million 2Health News:Collaboration to Create Pediatric Research Institute Receives $23 Million 3Health News:MSA Schedules Third Quarter Earnings Webcast 2Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 2Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 3Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 4Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 5Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 6Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 7Health News:Researchers study potential health benefits of natural chemicals in muscadine grape seeds 2Health News:Researchers study potential health benefits of natural chemicals in muscadine grape seeds 3Health News:PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product 2Health News:PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron (Total/Ferene). Storage temp: 15 - 30 C. Linearity: 0 - 500 ug/dl. Expected values: from males 60 - 160 ug/dl, from females 43 - 140 ug/dl. Available with Calibrator and Number of test are 120....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Medicine Products: